Press Releases

 
Press Releases
  Date Title and Summary View
Mar 14, 2007
WOBURN, Mass.--(BUSINESS WIRE)--March 14, 2007--ArQule, Inc. (NASDAQ: ARQL) today announced that the American Society of Clinical Oncology (ASCO) has accepted for oral presentation the Company's abstract for ARQ 197 (A Phase 1 Dose Escalation Study of ARQ 197, a Selective Inhibitor of the c-Met Receptor in Patients with Metastatic Solid Tum...
Feb 8, 2007
WOBURN, Mass.--(BUSINESS WIRE)--Feb. 8, 2007--ArQule, Inc. (NASDAQ: ARQL) today announced its financial results for the year and for the fourth quarter ended December 31, 2006. The Company reported a net loss of $31,440,000 or $0.88 per share, for the year ended December 31, 2006, compared with a net loss of $7,520,000, or $0.22 ...
Feb 8, 2007
WOBURN, Mass.--(BUSINESS WIRE)--Feb. 8, 2007--ArQule, Inc. (NASDAQ: ARQL) today announced that it will present at the BioCEO & Investor Conference on Wednesday, February 14, 2007 at 1:30 p.m. eastern time. ArQule's presentation will be webcast live and can be accessed through the investor relations section of the Company's website. The ...
Feb 1, 2007
WOBURN, Mass.--(BUSINESS WIRE)--Feb. 1, 2007--ArQule, Inc. (Nasdaq: ARQL) today announced that it will report its financial results for Fiscal 2006 year-end and fourth quarter on Thursday, February 8, 2007 at 7:00 a.m. (eastern time), and hold a conference call at 9:00 a.m. (eastern time). Dr. Stephen A. Hill, ArQule's president and chief e...
Jan 29, 2007
WOBURN, Mass.--(BUSINESS WIRE)--Jan. 29, 2007--ArQule, Inc. (NASDAQ: ARQL) and the chairman of its scientific advisory board, Dr. Chiang J. Li, today announced a $5.0 million sponsored research agreement with the newly established Boston Biomedical, Inc. (BBI), an independent corporation. ArQule and Dr. Li have agreed that he will transitio...
Jan 17, 2007
WOBURN, Mass.--(BUSINESS WIRE)--Jan. 17, 2007--ArQule, Inc. (Nasdaq: ARQL) today announced that Michael D. Loberg, Ph.D., has been named to its board of directors. Dr. Loberg brings 27 years of senior management and drug development experience to ArQule, including leadership positions at NitroMed, Inc. and Bristol Myers Squibb Company. ...
Jan 16, 2007
WOBURN, Mass.--(BUSINESS WIRE)--Jan. 16, 2007--ArQule, Inc. (NASDAQ: ARQL) today provided an update on its clinical trials with three compounds: ARQ 197, a proprietary, orally administered small molecule inhibitor of the c-Met receptor tyrosine kinase; ARQ 501, a first-generation Activated Checkpoint Therapy(SM) (ACT) candidate; and ARQ 171...
Page: FirstPrevious ...
29
= add release to Briefcase

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300